Vor Biopharma Inc. (VOR)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Robert Ang M.B.A., M.D., MBBS | President, CEO & Director | 943.91k | -- | 1975 |
Dr. Tirtha Chakraborty Ph.D. | Chief Scientific Officer | 661.98k | -- | 1973 |
Dr. Eyal C. Attar M.D. | Chief Medical Officer | 660.55k | -- | 1971 |
Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D. | Scientific Founder & Chairman of Scientific Advisory Board | -- | -- | 1971 |
Dr. Nathan D. Jorgensen M.B.A., Ph.D. | Chief Financial Officer | 608.48k | -- | 1977 |
Ms. Tania Philipp | Chief People Officer | -- | -- | 1972 |
Mr. John C. King M.B.A. | Chief Commercial Officer | -- | -- | 1976 |
Mr. Samir Vattompadam M.S. | Senior Vice President of Portfolio Strategy & Program Management | -- | -- | -- |
Mr. David Phillips M.B.A. | Senior VP & Head of Quality | -- | -- | -- |
Vor Biopharma Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 168
Description
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
August 8, 2024 at 10:59 AM UTC - August 12, 2024 at 12:00 PM UTC
Vor Biopharma Inc. Earnings Date
Recent Events
April 29, 2024 at 1:30 PM UTC
at Chardan Annual Genetic Medicines + Cell Therapy Manufacturing Summit